In Brief This Week: Roche NimbleGen; Aushon BioSystems; Saladax Biomedical; Mobidiag; Enigma Diagnostics

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

People In The News

Christopher Gleeson was named non-executive chairman at Osmetech, while Genome Canada tapped Thomas Caskey to serve as chair of its board, and more.

Cardiff Univ. Uses $6.6M for Neuro-Genetics and Genomics Center

The university will use funding from sources within the UK and its own funds for a center for neuropsychiatric gene-based and translational research.

Genome-Wide Screen Turns Up Primate-Specific Genes

A team of researchers from the US and Singapore used comparative genomics to find genes that are present in the genomes of primates but absent from those of non-primates.

CFI's 'Omics Grants Broad in Scope

Some of the $577 million is going to cancer genomics, DNA barcoding, and interactome studies.

Osmetech Raises $8.6M Through Private Placement

Osmetech placed roughly 262 million shares of stock at a price of 2p per share.

Bioethicists Call For Heightened Oversight of Genetic Ancestry Testing

In a policy paper appearing online today in Science, a group of American bioethicists highlighted gaps in genetic ancestry testing oversight — and offered suggestions for developing new standards.

Monogram Leads Gainers for June GWDN Index

The GWDN Index climbed 6 percent as tech stocks rallied during the month. Monogram Biosciences was the biggest gainer for the month, due to its acquisition pact with LabCorp.

Interleukin Sells Nutrition Branch for $4.6M

The genetic testing company sold the AJG business to a nutraceutical company to focus on its core business.

BlueGnome to Market Rubicon Technology for IVF Studies

BlueGnome will use the PicoPlex in its SurePlex DNA Amplification system.

Illumina Lowers Q2 Revenue Forecast Due to Order Delays

The company attributed the lower-than-expected revenue to a "shortfall" in its array business due to several factors, including order delays related to stimulus funding under the American Recovery & Reinvestment Act.

IOM Report Lists Comparative Effectiveness Priorities

The Institute of Medicine has laid out priority areas including some genomics and biomarker-focused studies that the stimulus funding should support.

Myriad Completes Spin Off of Pharma Business

Myriad Genetics' shareholders received shares in the pharma spin off. The firm also said it had retained the rights to claim $400 million in tax deductions.